Cullinan oncology announces updated phase 1/2a data for cln-081 in nsclc egfr exon 20 patients

Cln-081 continues to demonstrate a differentiated clinical profile at the recommended phase 2 dose of 100mg bid

CGEM Ratings Summary

CGEM Quant Ranking